New tests launched in January
New Tests
In January 2023, Mayo Clinic Laboratories announced fifty-nine new tests along with numerous reference value changes, obsolete tests, and algorithm changes.
The new tests that launched in January 2023 by Mayo Clinic Laboratories:
0752T | Digitization glass micro slide lv 3 (Bill Only)
This test is for tracking purposes only.
0753T | Digitization glass micro slide lv 4 (Bill Only)
This test is for tracking purposes only.
0754T | Digitization glass micro slide lv 5 (Bill Only)
This test is for tracking purposes only.
0755T | Digitization glass micro slide lv 6 (Bill Only)
This test is for tracking purposes only.
0756T | Digitize glass micro slide SS grp I (Bill Only)
This test is for tracking purposes only.
0757T | Digitize glass micro slide SS grp 2 (Bill Only)
This test is for tracking purposes only.
0758T | Digitize glass micro slide SS Frozn (Bill Only)
This test is for tracking purposes only.
0759T | Digitize glass micro slide SS grp 3 (Bill Only)
This test is for tracking purposes only.
0760T | Digitize glass micro slide IHC intl (Bill Only)
This test is for tracking purposes only.
0761T | Digitize glass micro slide IHC addl (Bill Only)
This test is for tracking purposes only.
0763T | Digitize glass micro slide IHC mrph (Bill Only)
This test is for tracking purposes only.
AGNTC | Anti-Glial/Neuronal Nuclear Antibody-Type 1 (AGNA-1) Titer, Spinal Fluid
This test is intended for reporting an end titer result from cerebrospinal fluid (CSF) specimens.
AGNTS | Anti-Glial/Neuronal Nuclear Antibody-Type 1 (AGNA-1) Titer, Serum
This test is intended for reporting an end titer result from serum specimens. This test is also useful for investigating neurological symptoms that appear during, or after, cancer therapy, and are not explainable by metastasis.
AHLP | AudioloGene Hearing Loss Panel, Varies
This test is intended for establishing a diagnosis of a syndromic or nonsyndromic hereditary hearing loss disorder.
AN1TC | Antineuronal Nuclear Antibody-Type 1 (ANNA-1) Titer, Spinal Fluid
This test is intended for establishing a diagnosis of paraneoplastic autoimmune neuropathies, encephalomyeloradiculopathies, related neurologic disorders, and intestinal pseudo-obstruction/dysmotility associated with small-cell lung carcinoma.
AN1TS | Antineuronal Nuclear Antibody-Type 1 (ANNA-1) Titer, Serum
This test is intended for establishing a diagnosis of paraneoplastic autoimmune neuropathies, encephalomyeloradiculopathies, related neurologic disorders, and intestinal pseudo-obstruction/dysmotility associated with small-cell lung carcinoma.
AN2TC | Antineuronal Nuclear Antibody Type 2 (ANNA-2) Titer, Spinal Fluid
This test is intended for investigating middle-aged or older patients who present with unexplainable signs of midbrain/cerebellar/brain stem disorder and/or myelopathy, especially women with a previous history of breast cancer, and both sexes if there is a history of tobacco abuse or passive exposure.
AN2TS | Antineuronal Nuclear Antibody Type 2 (ANNA-2) Titer, Serum
This test is intended for investigating a smoker presenting with 1 or more elements of encephalomyeloradiculoneuropathy as a part of PAVAL / Paraneoplastic, Autoantibody Evaluation, Serum.
AN3TC | Antineuronal Nuclear Antibody Type 3 (ANNA-3) Titer, Spinal Fluid
This test is intended for evaluating patients who present with a subacute neurological disorder of undetermined etiology and have risk factors for primary lung carcinoma.
AN3TS | Antineuronal Nuclear Antibody Type 3 (ANNA-3) Titer, Serum
This test is intended for evaluating patients who present with a subacute neurological disorder of undetermined etiology and have risk factors for primary lung carcinoma.
APBCC | Adaptor Protein 3 Beta2 (AP3B2) Antibody, Cell-Binding Assay, Spinal Fluid
This test is intended for the differential diagnosis of patients presenting with mixed cerebellar and sensory ataxia and myeloneuropathy.
APBCS | Adaptor Protein 3 Beta2 (AP3B2) Antibody, Cell-Binding Assay, Serum
This test is intended for the differential diagnosis of patients presenting with mixed cerebellar and sensory ataxia and myeloneuropathy.
APBTC | Adaptor Protein 3 Beta2 (AP3B2) Antibody, Tissue Immunofluorescence Titer, Spinal Fluid
This test is intended for the differential diagnosis of patients presenting with mixed cerebellar and sensory ataxia and myeloneuropathy. This test is also useful for reporting an end titer result from spinal fluid specimens.
APBTS | Adaptor Protein 3 Beta2 (AP3B2) Antibody, Tissue Immunofluorescence Titer, Serum
This test is intended for the differential diagnosis of patients presenting with mixed cerebellar and sensory ataxia and myeloneuropathy. This test is also useful for reporting an end titer result from serum specimens.
APHTC | Amphiphysin Antibody Titer Assay, Spinal Fluid
This test is intended for evaluating patients with recent onset of a subacute neurological disorder for which a paraneoplastic basis might be suspected, particularly if the patient has a previous history, risk factors, or family history of cancer, especially lung or breast cancer.
APHTS | Amphiphysin Antibody Titer Assay, Serum
This test is intended for evaluating patients with recent onset of a subacute neurological disorder for which a paraneoplastic basis might be suspected, particularly if the patient has a previous history, risk factors, or family history of cancer, especially lung or breast cancer.
CRMTC | Collapsin Response-Mediator Protein-5 (CRMP-5) Neuronal IgG Titer, Spinal Fluid
This test is intended for the evaluation of neuroautoimmunity, particularly small-cell lung carcinoma and thymoma, in conjunction with other antineuronal antibodies.
CRMTS | Collapsin Response-Mediator Protein-5 (CRMP-5) Neuronal IgG Titer, Serum
This test is intended for the evaluation of neurological autoimmunity particularly that associated with small-cell lung carcinoma and thymoma.
ECHNG | Echinococcus Antibody, IgG, Serum
This test is intended for the detection of antibodies to Echinococcus species, including Echinococcus multilocularis and Echinococcus granulosus.
EHOLG | Entamoeba histolytica Antibody, Serum
This test is intended as an adjunct in the diagnosis of extraintestinal, invasive amebiasis.
GFATC | Glial Fibrillary Acidic Protein Alpha Subunit Antibody, Immunofluorescence Titer Assay, Spinal Fluid
This test is intended for distinguishing, in spinal fluid, autoimmune GFAP astrocytopathy from infectious meningoencephalitis and idiopathic inflammatory central nervous system (CNS) disorders such as multiple sclerosis, vasculitis and sarcoidosis, disorders commonly considered in the differential diagnosis.
GFATS | Glial Fibrillary Acidic Protein Alpha Subunit Antibody, Immunofluorescence Titer Assay, Serum
This test is intended for distinguishing autoimmune glial fibrillary acidic protein (GFAP) astrocytopathy from infectious meningoencephalitis and idiopathic inflammatory central nervous system (CNS) disorders such as multiple sclerosis, vasculitis and sarcoidosis, disorders commonly considered in the differential diagnosis. This test is also useful for alerting the clinician that the patient has an immune-mediated, steroid-responsive disorder and to search for a malignancy.
HELIS | Helicobacter pylori Culture with Antimicrobial Susceptibilities, Varies
This test is intended for the recovery of Helicobacter pylori from gastric specimens for antimicrobial susceptibility testing of the organism (amoxicillin, clarithromycin, levofloxacin, metronidazole, rifampin, and tetracycline are routinely tested).
IL6DX | Interleukin-6, Serum
This test is intended for evaluating patients with suspected chronic inflammatory disorders, such as rheumatoid arthritis, systemic lupus erythematosus, ankylosing spondylitis, or inflammatory bowel disease.
NCDCC | Neurochondrin Antibody, Cell-Binding Assay, Spinal Fluid
This test is intended for evaluating neurochondrin-IgG by cell-binding assay using spinal fluid from patients presenting with cerebellar and brainstem syndrome.
NCDCS | Neurochondrin Antibody, Cell-Binding Assay, Serum
This test is intended for evaluating neurochondrin-IgG by cell-binding assay using serum from patients presenting with cerebellar and brainstem syndrome.
NCDTC | Neurochondrin Antibody, Tissue Immunofluorescence Titer, Spinal Fluid
This test is intended for detecting neurochondrin-IgG in spinal fluid (CSF) from patients presenting with cerebellar and brainstem syndrome.
NCDTS | Neurochondrin Antibody, Tissue Immunofluorescence Titer, Serum
This test is intended for detecting neurochondrin-IgG in serum from patients presenting with cerebellar and brainstem syndrome.
PC1TC | Purkinje Cell Cytoplasmic Antibody Type 1 (PCA-1) Titer, Spinal Fluid
This test is intended for identifying female patients whose subacute cerebellar degeneration or peripheral neuropathy is due to a remote (autoimmune) effect of gynecologic or breast carcinoma.
PC1TS | Purkinje Cell Cytoplasmic Antibody Type 1 (PCA-1) Titer, Serum
This test is intended for identifying female patients whose subacute cerebellar degeneration or peripheral neuropathy is due to a remote (autoimmune) effect of gynecologic or breast carcinoma.
PC2TC | Purkinje Cell Cytoplasmic Antibody Type 2 (PCA-2) Titer, Spinal Fluid
This test is intended for evaluating patients who present with a subacute neurological disorder of undetermined etiology and have risk factors for lung cancer.
PC2TS | Purkinje Cell Cytoplasmic Antibody Type 2 (PCA-2) Titer, Serum
This test is intended for evaluating patients who present with a subacute neurological disorder of undetermined etiology and have risk factors for lung cancer.
PCTTC | Purkinje Cell Cytoplasmic Antibody, Type Tr (PCA-Tr) Titer, Spinal Fluid
This test is intended for serological testing for Purkinje cell cytoplasmic antibody-Tr for patients with acquired cerebellar ataxia of undetermined etiology, particularly if the patient has a history of Hodgkin lymphoma.
PCTTS | Purkinje Cell Cytoplasmic Antibody Type Tr (PCA-Tr) Titer, Serum
This test is intended for serological testing for Purkinje cell cytoplasmic antibody-Tr for patients with acquired cerebellar ataxia of undetermined etiology, particularly if the patient has a history of Hodgkin lymphoma.
SP5CC | Septin-5 Antibody, Cell-Binding Assay, Spinal Fluid
This test is intended for detecting septin-5 IgG by cell-binding assay using cerebrospinal fluid specimens.
SP5CS | Septin-5 Antibody, Cell Binding Assay, Serum
This test is intended for detecting septin-5 IgG by cell-binding assay using serum specimens.
SP5TC | Septin-5 Antibody, Tissue Immunofluorescence, Spinal Fluid
This test is intended for detecting septin-5 IgG in spinal fluid (CSF) specimens.
SP5TS | Septin-5 Antibody, Tissue Immunofluorescence Titer, Serum
This test is intended for detecting septin-5 IgG in serum specimens.
SP7CC | Septin-7 Antibody, Cell-Binding Assay, Spinal Fluid
This test is intended for detecting septin-7 IgG by cell-binding assay using cerebrospinal fluid specimens.
SP7CS | Septin-7 Antibody, Cell-Binding Assay, Serum
This test is intended for detecting septin-7 IgG by cell-binding assay using serum specimens.
SP7TC | Septin-7 Antibody, Tissue Immunofluorescence Titer, Spinal Fluid
This test is intended for detecting septin-7 IgG in cerebrospinal fluid (CSF) specimens.
SP7TS | Septin-7 Antibody, Tissue Immunofluorescence Titer, Serum
This test is intended for detecting septin-7 IgG in serum specimens.
ST2S | ST2, Serum
This test is intended for aiding in prognosis for patients diagnosed with chronic heart failure.
TRCNG | Trichinella Antibody, IgG, Serum
This test is intended as an adjunct in the diagnosis of trichinosis.
TTBS | Testosterone, Total and Bioavailable, Serum
This test is intended for the assessment of second-level test for suspected increases or decreases in physiologically active testosterone.
TTFB | Testosterone, Total, Bioavailable, and Free, Serum
This test is intended for second- or third-order test for evaluating testosterone status (eg, when abnormalities of sex hormone-binding globulin are present).
TOXCG | Toxocara Antibody, IgG, Serum
This test is intended for aiding in the diagnosis of Toxocara infection.
WNDZ | Wilson Disease, ATP7B Full Gene Sequencing with Deletion/Duplication, Varies
This test is intended for confirming the diagnosis of Wilson disease.
In addition to these tests, the department also announced several test changes. Click the links below to view test changes announced by Mayo Clinic Laboratories: